HONG KONG – Increasingly concerned that the unchecked use of antibiotics is rapidly creating widespread resistance, regulators in Asia are developing stronger regulations and controls.
HONG KONG – Increasingly concerned that the unchecked use of antibiotics is rapidly creating widespread resistance, regulators in Asia are developing stronger regulations and controls.
HONG KONG – Stepped up regulations and a curb on the use of antibiotics is hurting the bottom line of antibiotic makers in China. And there is little chance of a change any time soon.
HONG KONG – With a green light from the CFDA, Taiwan antibiotics maker Taigen Biotechnology Co. Ltd. now has the first made-in-Taiwan novel drug marketed in mainland China.
HONG KONG – With a green light from the CFDA, Taiwan antibiotics maker Taigen Biotechnology Co. Ltd. now has the first made-in-Taiwan novel drug marketed in mainland China.
HONG KONG – Aiming to address a perceived disparity in the quality of manufacturing of drugs for the China market, the CFDA is ramping up its focus on offshore drug manufacturers. The regulator last year stepped up the number of overseas good manufacturing practice (GMP) inspections it carried out, while domestically, it put more of the onus on companies to police themselves.
HONG KONG – Catching up with international markets, China is unbinding its drug manufacturing licensing regime from the marketing authorization in a move aimed at revolutionizing the country's drug development space.
